Literature DB >> 21114130

The risk factors and the treatment course of cerebral venous thrombosis: an experience of 41 cases.

Mohammad Ali Sahraian1, Hooshang Akbari, Mohammad Reza Khajavi, Atabak Najafi, Patricia Khashayar.   

Abstract

BACKGROUND: The present study was designed to describe the characteristics, risk factors and prognosis of patients diagnosed with CVT in our center.
METHOD: The present retrospective cross-sectional study was conducted on patients diagnosed with cerebral vein or sinus thrombosis based on the patients' clinical presentation and the findings of the imaging studies between 2003 and 2008. The patients were studied for possible risk factors and the resultant outcome after terminating the therapeutic course.
RESULTS: Headache, the most common symptom reported in 80% of the cases, was considered the first symptom in only 46% of these patients. Coma, focal motor deficit at presentation, hemorrhagic conversion of infarction and thrombosis in more than one sinus were factors associated with unfavorable outcome in these patients.
CONCLUSION: Physicians should always have CVT in mind while examining patients particularly women on pills who complain about headache. More studies however are needed to point out more specific presentations which would lead to the early diagnosis of CVT in the patients.

Entities:  

Mesh:

Year:  2010        PMID: 21114130

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN: 0300-9009            Impact factor:   2.396


  2 in total

1.  Cerebral venous sinus thrombosis in iran: cumulative data, shortcomings and future directions.

Authors:  Afshin Borhani Haghighi; Nahid Ashjazadeh; Anahid Safari; Salvador Cruz-Flores
Journal:  Iran Red Crescent Med J       Date:  2012-12-06       Impact factor: 0.611

2.  Clinical features, risk factors, and outcome of cerebral venous thrombosis in Tehran, Iran.

Authors:  Samira Yadegari; Askar Ghorbani; S Roohollah Miri; Mohammad Abdollahi; Mohsen Rostami
Journal:  J Neurosci Rural Pract       Date:  2016 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.